S. Morisset

发表

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia

G. Salles, A. Plesa, C. Dumontet, 2017, World journal of stem cells.

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients

X. Thomas, F. Barraco, F. Nicolini, 2013, Cancer.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

P. Rousselot, F. Nicolini, L. Roy, 2018, Experimental hematology.

High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation

G. Salles, X. Thomas, F. Barraco, 2014, Bone Marrow Transplantation.

Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia.

A. Plesa, C. Dumontet, X. Thomas, 2013, World journal of stem cells.

Dynamic LTR retrotransposon transcriptome landscape in septic shock patients

D. Maucort-Boulch, Aidan MacNamara, T. Rimmele, 2020, Critical Care.

Using EasyMatch® to anticipate the identification of an HLA identical unrelated donor: A validated efficient time and cost saving method.

X. Thomas, Y. Bertrand, F. Barraco, 2016, Human immunology.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia

P. Cony-Makhoul, C. Preudhomme, I. Tigaud, 2018, Haematologica.

Serotyping of Toxoplasma gondii: striking homogeneous pattern between symptomatic and asymptomatic infections within Europe and South America.

J. Lobry, J. Gómez‐Marín, M. Demar, 2008, Microbes and infection.

Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens.

X. Thomas, F. Barraco, F. Nicolini, 2012, Experimental hematology.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

J. Reiffers, E. Lippert, S. Hayette, 2014, Haematologica.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line

B. Turcq, S. Hayette, I. Tigaud, 2019, Annals of Hematology.

Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

I. Yakoub-Agha, D. Blaise, M. Mohty, 2015, Bone Marrow Transplantation.

Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib.

P. Cony-Makhoul, S. Hayette, F. Mahon, 2018, Experimental hematology.

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Martin C. Müller, I. Dufva, G. Martinelli, 2011, Blood.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

P. Rousselot, F. Mahon, F. Nicolini, 2017, Cancer.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

F. Durrieu, B. Turcq, S. Hayette, 2019, Cancer medicine.

CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.

P. Cony-Makhoul, F. Nicolini, M. Sobh, 2016, Leukemia research.

Tacrolimus Extended Release could be an Alternative to the use of Cyclosporine after Allogeneic HSCT in case of Renal Impairment due to Cyclosporine: A Prospective pilot study from two centers in France

C. Rioufol, F. Barraco, A. Perrot, 2017 .

Oral cyclosporine A in neonatal swines for transplantation studies

J. Dubernard, A. Gazarian, M. Sobh, 2015, Immunopharmacology and immunotoxicology.

Oral cyclosporine A in neonatal swines for transplantation studies

J. Dubernard, A. Gazarian, M. Sobh, 2015, Immunopharmacology and immunotoxicology.

Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France

N. Garrec, F. Galactéros, E. Bernit, 2021, American journal of hematology.

Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.

P. Vanhems, X. Thomas, F. Nicolini, 2011, Medical mycology.

HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns.

X. Thomas, V. Escuret, F. Barraco, 2016, The Journal of infection.

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry

R. Brand, J. Finke, N. Russell, 2010, Leukemia.

High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia

G. Salles, A. Plesa, J. Magaud, 2012, PloS one.

Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.

M. Robin, I. Yakoub-Agha, D. Blaise, 2013, Experimental hematology.

Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.

D. Blaise, M. Mohty, P. Moreau, 2013, Experimental hematology.

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

D. Blaise, M. Mohty, J. Bay, 2012, Annals of Hematology.

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

P. Rousselot, F. Mahon, F. Nicolini, 2016 .

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

I. Yakoub-Agha, P. Rohrlich, F. Barraco, 2014 .

Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.

D. Blaise, M. Mohty, J. Bay, 2013, Experimental hematology.

Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings

X. Thomas, F. Barraco, F. Nicolini, 2015, Leukemia & lymphoma.

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a Flamsa Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

P. Chevallier, M. Mohty, X. Thomas, 2011 .

Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS

M. Robin, D. Blaise, G. Guillerm, 2023, Bone Marrow Transplantation.

Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French–Swiss retrospective study

I. Yakoub-Agha, J. Tiercy, F. Barraco, 2015, Bone Marrow Transplantation.

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.

P. Rousselot, F. Mahon, F. Nicolini, 2019, Blood.

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

H. Dombret, S. Leprêtre, R. Gressin, 2021, Clinical lymphoma, myeloma & leukemia.

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR4.5. Preliminary Results of a Phase II Study.

P. Cony-Makhoul, P. Rousselot, F. Mahon, 2012 .

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study

P. Cony-Makhoul, S. Hayette, P. Rousselot, 2023, British journal of haematology.

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

P. Cony-Makhoul, T. Henni, P. Rousselot, 2022, Haematologica.

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients

J. Drai, E. Blond, F. Mahon, 2016, Haematologica.

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

P. Cony-Makhoul, E. Deconinck, P. Rousselot, 2019, Blood.

Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

J. Reiffers, E. Lippert, S. Hayette, 2012 .

Treatment of granular cell tumor via complete right lung resection in a horse.

J. Sojka, S. Adams, P. Facemire, 2000, Journal of the American Veterinary Medical Association.

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

P. Cony-Makhoul, I. Tigaud, A. Delmer, 2023, Leukemia research.

Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda.

X. Thomas, M. Le Maréchal, M. Michallet, 2018, Medecine et maladies infectieuses.

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

L. Fornecker, C. Récher, K. Laribi, 2022, Cancer Medicine.

On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

M. Robin, P. Chevallier, I. Yakoub-Agha, 2023, Acta Haematologica.

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

P. Feugier, S. Leprêtre, R. Letestu, 2023, Blood advances.

Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France

A. Plesa, S. Hayette, I. Tigaud, 2023, Cancer medicine.

Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study

D. Maucort-Boulch, T. Rimmele, A. Friggeri, 2017, Intensive Care Medicine.

Decreased CX3CR1 messenger RNA expression is an independent molecular biomarker of early and late mortality in critically ill patients

D. Maucort-Boulch, J. Viale, T. Rimmele, 2016, Critical Care.

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Martin C. Müller, I. Dufva, G. Martinelli, 2010 .